Lipella Pharmaceuticals (NASDAQ:LIPO – Get Free Report) and Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
Profitability
This table compares Lipella Pharmaceuticals and Bolt Biotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lipella Pharmaceuticals | -988.83% | -224.08% | -172.88% |
| Bolt Biotherapeutics | -611.47% | -126.23% | -54.70% |
Earnings and Valuation
This table compares Lipella Pharmaceuticals and Bolt Biotherapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lipella Pharmaceuticals | $536,357.00 | 0.28 | -$5.02 million | ($2.42) | -0.01 |
| Bolt Biotherapeutics | $7.70 million | 1.00 | -$33.38 million | ($16.44) | -0.24 |
Lipella Pharmaceuticals has higher earnings, but lower revenue than Bolt Biotherapeutics. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Lipella Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
74.3% of Lipella Pharmaceuticals shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 32.1% of Lipella Pharmaceuticals shares are held by insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Lipella Pharmaceuticals and Bolt Biotherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lipella Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
| Bolt Biotherapeutics | 1 | 1 | 2 | 0 | 2.25 |
Bolt Biotherapeutics has a consensus price target of $14.50, indicating a potential upside of 264.32%. Given Bolt Biotherapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Lipella Pharmaceuticals.
Volatility and Risk
Lipella Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
Summary
Bolt Biotherapeutics beats Lipella Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
About Bolt Biotherapeutics
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
